Tivozanib hydrochloride hydrate

Research use only, not for human use.

Tivozanib hydrochloride hydrate (AV-951 hydrochloride hydrate) is an orally active, selective, and potent vascular endothelial growth factor receptor (VEGFR) tyrosine kinase inhibitor that inhibits VEGFR-1, VEGFR-2, and VEGFR-3.

Tivozanib hydrochloride hydrate is a selective and orally activeVEGFR tyrosine kinase inhibitor with IC50 of 0.21, 0.16, 0.24 nM for VEGFR-1, VEGFR-2, VEGFR-3, respectively. Tivozanib hydrochloride hydrate inhibits angiogenesis and vascular permeability in tumor tissues and shows antitumor activity. Tivozanib hydrochloride hydrate has the potential for the research of metastatic renal cell carcinoma (RCC).

Tivozanib hydrochloride hydrate inhibits the phosphorylation of VEGFR-1, VEGFR-2 and VEGFR-3.

Tivozanib hydrochloride hydrate (1 mg/kg; p.o.; 14 days) suppresses the development of CNV lesions and leds to a significant regression of established CNV, reducing the affected areas by 67.7%.

——

Angiogenesis

VEGFR

VEGFR

——

——

682745-41-1

509.34

C22H22Cl2N4O6

>98% (HPLC)

In Vitro:?DMSO : 250 mg/mL (490.83 mM; Ultrasonic )

O.Cl.COc1cc2nccc(Oc3ccc(NC(=O)Nc4cc(C)on4)c(Cl)c3)c2cc1OC

——

(-20℃)

With Ice Pack

≥ 2 years